Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

462
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
462

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differential roles of alexithymia components in linking autistic traits to personal distress and empathy concern.

Frontiers in psychology·2026
Same author

Lasiokaurin suppresses hepatocellular carcinoma proliferation and induces apoptosis via the JAK2/STAT3 pathway.

Journal of molecular histology·2026
Same author

Experimental evolution to thermal stress indicates climate resilience in a cosmopolitan arthropod.

eLife·2026
Same author

CDC20 promotes prostate cancer progression via modulating c-MYC and PI3K-AKT signaling.

iScience·2026
Same author

From exposure to infection: mechanisms linking emerging pollutants to increased viral susceptibility.

International journal of environmental health research·2026
Same author

Predicting Frailty Trajectories Using Interpretable Machine Learning Among Older Adults Following Hip Surgery: Prospective Longitudinal Study.

JMIR aging·2026
Same journal

Correction: Fukushima et al. Long-Term Immunogenicity of Rabies Pre-Exposure Prophylaxis in Japanese Adult Travelers: Comparison of Dosing Regimens. <i>Vaccines</i> 2025, <i>13</i>, 1169.

Vaccines·2026
Same journal

Access to Vaccines Among Asylum Seekers, Refugees, and Undocumented Migrants Across the Migratory Cycle in the European Union, European Economic Area, Switzerland and the United Kingdom: A Scoping Review.

Vaccines·2026
Same journal

Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.

Vaccines·2026
Same journal

Insights from 25 Years of Measles and Measles-Rubella Vaccination Campaigns in the WHO African Region (2001-2025).

Vaccines·2026
Same journal

Post-Marketing Safety Surveillance of Influenza Vaccines in Anhui Province, China, 2016-2025.

Vaccines·2026
Same journal

Characteristics of Hypotonic-Hyporesponsive Episodes (HHEs) Following Childhood Vaccination: A 13-Year Analysis of Spontaneous Reports to the Dutch Pharmacovigilance Centre Lareb.

Vaccines·2026
See all related articles

Related Experiment Video

Updated: May 25, 2025

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.1K

HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization.

Rui Han1,2, Yujun Luo1,2, Jingdong Gao1,2,3

  • 1Oncology Department of Chinese Medicine, The First Affiliated Hospital of Naval Medical University, Shanghai 200433, China.

Vaccines
|February 26, 2025
PubMed
Summary
This summary is machine-generated.

Histone deacetylase 3 (HDAC3) reshapes the tumor immune microenvironment, turning cold tumors hot. HDAC3 inhibitors offer a promising strategy to enhance cancer immunotherapy efficacy and patient outcomes.

Keywords:
HDAC3combination therapyimmune modulationtumor immunotherapytumor microenvironment

More Related Videos

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.5K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.7K

Related Experiment Videos

Last Updated: May 25, 2025

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.1K
Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

6.5K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

9.7K

Area of Science:

  • Epigenetics
  • Cancer Immunology
  • Immunotherapy

Background:

  • Histone deacetylase 3 (HDAC3) is a key epigenetic regulator in cancer.
  • HDAC3 influences tumor progression and immune cell function.
  • Targeting HDAC3 presents a novel strategy for cancer immunotherapy.

Purpose of the Study:

  • To comprehensively explore the multifaceted roles of HDAC3 in cancer.
  • To investigate HDAC3's regulation of immune-modulatory pathways.
  • To examine HDAC3's effects on various immune cell types and the tumor immune microenvironment.

Main Methods:

  • Exploration of HDAC3's regulation of cGAS-STING, ferroptosis, and Nrf2/HO-1 pathways.
  • Analysis of HDAC3's impact on T cells, NK cells, dendritic cells, and macrophages.
  • Review of therapeutic strategies involving HDAC3 inhibitors.

Main Results:

  • HDAC3 modulates key immune pathways crucial for anti-tumor immunity.
  • HDAC3 enhances immune cell functions, including T cell activation and NK cell cytotoxicity.
  • HDAC3 converts immunologically "cold" tumors into "hot" tumors, improving immunotherapy response.

Conclusions:

  • HDAC3 inhibition is a promising therapeutic strategy for cancer immunotherapy.
  • HDAC3 inhibitors can be used alone or in combination with other treatments to overcome resistance.
  • Innovative strategies like selective inhibitors and advanced delivery systems can enhance HDAC3-targeted therapy efficacy and safety.